Men and women age differently. This presentation will discuss the differences for women and assist the learner to increase treatment skills.
(Handouts)

During this session, the speaker will discuss matters of particular importance to women infected with HIV including, cervical cancer screening, contraception modalities, and reproduction issues.
(Handouts)

Do not fear the initiative to treat HCV in your clinic. It is not that difficult when it is a team effort. Organizational structure, planning, and tools to support treatment in this complicated patient population will be discussed.
(Handouts)

The speaker will discuss emerging issues of organ-specific side effects, signs and symptoms of early toxicity, and appropriate changes in the antiretroviral regimen.
(Handouts)

Tuberculosis remains a leading cause of death among HIV-infected patients worldwide. Annual screening for latent TB infection remains an important recommended prevention strategy in HIV-infected individuals. Diagnosing and treating active tuberculosis in HIV-infected individuals can be challenging due to the often atypical presentation and drug-drug interactions among anti-TB and HIV therapies. This session will utilize cases to review screening and treatment of latent TB infection, clinical presentation of active TB disease, and treatment of active TB.
(Handouts)

The speaker will discuss the most common and most severe potential complications of antiretroviral therapy.  Patient cases will be used to demonstrate potential complications of therapy and how to promptly recognize, manage and/or prevent adverse events from therapy.
(Handouts)

All patients with HIV infection should be screened for sexually transmitted diseases at baseline and annually; patients at increased risk should receive screening at 3- to 6-month intervals. Getting the information about sexual practices and habits can be a challenge based on the cultural and personal point of view. In this section, tools will be
discussed outlining different strategies to obtain an accurate sexual history.
(Handouts)

The speaker will describe motivational interviewing techniques that can be utilized to encourage patients with HIV to make important lifestyle and behavioral modifications to improve overall health.  These changes may be aimed at a variety of desired outcomes including adherence to antiretroviral therapy, cessation of drugs, alcohol, or tobacco use, and risk reduction.
(Handouts)

A series of case presentations will be used to illustrate the diagnosis and treatment of the most commonly encountered STD infections in HIV patients. The speaker will review the newest treatment guidelines of STD infections, and describe the resources available to assist the clinician with management of STD infections in immunocompromised patients.
(Handouts)

Different mechanisms of resistance patterns, as well as the specific role the therapeutic agents play while attacking the virus during different stages of the viral replication cycle, will be discussed. This interactive session will also demonstrate how to interpret resistance tests of patients with simple and complex resistance patterns. Indications for ordering genotypes, virtual phenotypes, and phenotypes will be reviewed.
(Handouts)

Differences in drug disposition and response between pediatric and adult patient populations are substantial. Pharmacokinetic variability due to the differing body compositions of pediatric and adult patients, changes in drug distribution and elimination related to maturation, as well as endocrinologic effects associated with the changes at puberty all make pediatric and adolescent patients significantly different from adults in terms of dosing medications. Limited data in the pediatric and adolescent population make administration of HAART medications particularly challenging. This session will focus on some of the pharmacokinetic (PK) and pharmacodynamic (PD) differences and major drug interactions seen in HIV infected children and adolescents.
(Handouts)

With the advent of antiretroviral therapy, there has been a dramatic reduction in the survival of HIV-infected patients; however this has resulted in increasing prevalence of renal disease even among young people. The incidence of renal complications has increased in part due to the primary infection and in part due to the nephrotoxic effects of HAART medications. HIV associated nephropathy (HIVAN) is the most common and aggressive of the renal diseases that can occur with HIV infection progressing to end stage renal disease within months. This session will discuss the different renal diseases seen with HIV infection in children and adolescents as well as identify renal risk factors before initiation of and during antiretroviral therapy, including the interplay between underlying renal disease and nephrotoxicity associated with medications.
(Handouts)

Antiretroviral drug interactions contribute to the complexity of managing HIV-infected patients.  The speaker will review the mechanisms of drug-drug interactions and discuss the most common and/or significant drug-drug interactions involving antiretroviral therapy.  The participant will be provided resources to assist in the assessment and management of drug-drug interactions.
(Handouts)

Information from recent conferences will be reviewed on issues of aging in the HIV-infected population. The speaker will address the importance of patient education to reduce risk factors, as well as recommendations for monitoring and screening and treatment and follow-up.
(Handouts)

HIV prevention intervention is always a challenge with adolescents.  This will be a panel presentation and discussion of previously tested effective interventions along with a demonstration of available resources.  The use of peer counselors and specifically HIV positive youth to communicate the message to other youth will be demonstrated.
(Handouts)

HIV is a changing epidemic with significant impact on psychiatry disorders due to multiple reasons (i.e. drug abuse, medication side effects, and drugs interactions).  The challenging of the mental illness & patient population characteristics require team approach and a multidisciplinary care for a adequate management.
(Handouts)